How is the progress of the world's first new drug for schizophrenia approved in the US and in the Chinese market
嬲乜黄
发表于 昨天 20:43
1165
0
0
On September 26th local time, the US Food and Drug Administration (FDA) announced the approval of BMS's schizophrenia drug Cobenfy (KarXT, xanomiline and trospium chloride) for the treatment of adult schizophrenia patients.
This is the first approved new mechanism therapy for schizophrenia in decades, targeting cholinergic receptors instead of dopamine receptors, which have long been the standard treatment.
The epidemiological survey of the World Health Organization shows that there are approximately 24 million schizophrenia patients worldwide in 2022. According to Expert Market Research, the global market size for schizophrenia drugs is estimated to grow from $8.18 billion in 2023 to $12.97 billion in 2032, with a compound annual growth rate of 5.26%.
On January 29th of this year, the well-known pharmaceutical website FINECE Pharma released the top 10 most anticipated drugs for 2024, and Cobenfy was listed as the first of the top 10 most anticipated drugs for 2024, with an expected sales revenue of $2.8 billion in 2028.
KarXT is a drug composed of xanomeline (an M1/M4 receptor agonist) and trospium (a non selective muscarinic antagonist), originally developed by Karuna Therapeutics. At the end of 2023, BMS spent $14 billion to acquire Karuna, obtaining this drug and other pipelines. The collaboration between Zaiding Pharmaceutical (09688. HK) and Karuna originated in 2021. At present, Zaiding Pharmaceutical owns the development, production, and commercialization rights of KarXT in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.
Public data shows that there are over 8 million patients with schizophrenia in China. KarXT has been approved in the United States, bringing hope to Chinese patients.
According to NextPharma, the global new drug database of the Medical Magic Cube, there are currently only 16 new drugs under development for schizophrenia in China that have entered clinical trials, and most of them are still dopamine receptor and 5-HT receptor targeted drugs. KarXT is one of the two drugs that have progressed to Phase III clinical stage and is expected to become the next approved new drug for schizophrenia in China. Another drug entering phase III clinical stage is the Gly-T1 inhibitor Iclepertin, developed by Boehringer Ingelheim.
Zaiding Pharmaceutical stated that in August 2024, KarXT's registered study UNITE-1 for schizophrenia had completed the enrollment of all mainland Chinese patients. It is expected to obtain key research data from 2024 to the first half of 2025 and submit a new drug application for KarXT for schizophrenia in mainland China.
In July of this year, Zaiding Pharmaceutical also joined the global Phase III ADEPT-2 study in Greater China to evaluate the safety and efficacy of KarXT in the treatment of Alzheimer's disease related psychiatric disorders.
Affected by the positive news of KarXT's approval for listing in the United States, Zaiding Pharmaceutical rose 10.96% to close at HKD 18.02 per share on September 27th, with a total market value of HKD 17.9 billion.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Warning of delisting, Chinese market failure, Polestar Motors "under siege"
- Tesla's sales in the Chinese market exceeded 55000 units in May, a year-on-year increase of 30%
- Johnson&Johnson Long acting Schizophrenic Therapy Approved in China
- Stop production of 4680 batteries? Tesla responded that "production is proceeding smoothly" and the Chinese market is promoting a "5-year zero interest" car purchase policy, causing its stock price to rise!
- Interview with McDonald's CEO in China: Investing in and Developing Smart Supply Chain in the Chinese Market with Long Term Optimism
- Apple Quarterly Report: iPad Sales Boost Overall Revenue, Chinese Market Declines More Than Expected
- Zaiding Medicine: Clinical study of KarXT for the treatment of schizophrenia completed, enrolled patients from mainland China
- Shadow over Est é e Lauder: Disappointed in the Chinese market, net profit plummets by over 60%
- New Consumption Observation: Revenue in the Chinese market skyrockets by nearly 40%. Lululemon continues to add: new store expansion will be heavily concentrated in China
- 13 routes, 42 destinations, and 96 voyages... Viking Cruises will customize their 2025 season for the Chinese market using "addition and subtraction"
-
大雪と網易が「複合」した後、大雪系傘下のゲームが次々と国服に復帰しつつあり、9月25日、魔獣世界に続き、大雪系ゲームの「現金牛」、カードゲーム「炉石伝説」が正式に国服に復帰した。午前7時26分、新京報貝殻 ...
- vvsky
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上証報中国証券網(何奎記者)は9月25日、国内頭部保険電子商取引サービスプラットフォームの慧択氏が米国株の開場前に発表した2024年第2四半期の未監査業績報告によると、上半期の慧択全プラットフォームによる総 ...
- 18010063851
- 前天 11:44
- 支持
- 反对
- 回复
- 收藏
-
百勝中国9月23日のニュースによると、百勝中国と保利発展ホールディングスはこのほど、広州保利発展広場で戦略協力協定に調印した。双方はそれぞれのビジネス分野での技術、管理、ブランドの優位性を十分に利用し、 ...
- 寒郁轩良
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
【世界市場】1、納指は0.04%、ダウは0.70%、スタンダードは0.19%下落した。2、英偉達は2%超上昇し、美光科技の株価は10%超上昇した。3、ナスダック中国の金龍指数は2.80%、蔚来は5%近く下落した。4、国際原油価格は ...
- 虚空一粒沙2017
- 前天 21:42
- 支持
- 反对
- 回复
- 收藏